PSA and bone scintigraphy

International Journal of Biological Markers

Volumn 12, Issue 4, 1997, Pages 158-161

  Modoni, S ^a,b   Calo E ^a   Nardella, G ^a   Ritrovato, G ^a   Frusciante, V ^a  

^a CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^b Dipartimento di Medicina Nucleare   (Italy)

Author keywords

Bone scintigraphy; Prostate cancer; PSA

Indexed keywords

MEDRONATE TECHNETIUM TC 99M; PROSTATE SPECIFIC ANTIGEN; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; BONE METASTASIS; BONE SCINTISCANNING; FOLLOW UP; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; PROSTATE CANCER; PROSTATECTOMY; SOFT TISSUE CANCER;

EID: 0031428953     PISSN: 03936155     EISSN: None     Source Type: Journal    
DOI: 10.1177/172460089701200404     Document Type: Article

References (12)

1. Leo ME, Bilhartz DL, Bergstrahl EJ, Oesterling JE. Prostate specific antigen in hormonally treated stage D2 prostate cancer: Is it always an accurate indicator of disease status? J Urol 1991; 145: 802-6.
2. Stamey TA, Kabalin JN, Ferrari M, Yang N. Prostate-specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. IV. Anti-androgen treated patients. J Urol 1989; 141: 1088-90.
3. Oesterling JE. Prostate specific antigen: A critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 1991; 145: 907-23.
4. Gleave ME, Coupland D, Drachenburg D, et al. Ability of serum prostate specific antigen levels to predict normal bone scans in patients with newly diagnosed prostate cancer. Urology 1996; 47: 708-12.
5. Chybowsky FM, Larson Keller JJ, Bergstrahl EJ, Oesterling JE. Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: prostate specific antigen is superior to all other clinical parameters. J Urol 1991; 145: 313-8.
6. Vijayakumar V, Vijayakumar S, Quadri SF, Blend MJ. Can prostate-specific antigen levels predict bone scan evidence of metastases in newly diagnosed prostate cancer? Am J Clin Oncol 1994; 17: 432-6.
7. Terris MK, Klonecke AS, McDougall IR, Stamey TA. Utilization of bone scan in conjuction with prostate-specific antigen levels in the surveillance for recurrence of adenocarcinoma after radical prostatectomy. J Nucl Med 1991; 32: 1713-7.
8. Freitas JE, Gilvydas R, Ferry JD, Gonzalez JA. The clinical utility of prostate-specific antigen and bone scintigraphy in prostate cancer follow-up. J Nucl Med 1991; 32: 1387-90.
9. Schultze H, Isaacs JT. Biology and therapy of prostatic cancer. Cancer Surveys 1986; 5 (3): 79-94.
10. Figg WD, Ammerman K, Patronas N, et al. Lack of correlation between prostate-specific antigen and the presence of measureable soft tissue metastases in hormone-refractory prostate cancer. Cancer Invest 1996; 14: 513-7.
11. Bruchowsky N, Brown EM, Coppin CM, et al. The endocrinology and treatment of prostate tumor progression. In: Current concepts and approaches to the study of prostate cancer. New York: Alan R Liss Inc. 1987; 347-87.
12. Stamey TA, Kabalin JN. Prostate-specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. I. Untreated patients. J Urol 1989; 141: 1070-5.